Scholarlink

<p>Acute myeloid leukaemia (AML) is a clonal disorder of the bone marrow, attributable to genetic alterations leading to clonal stem cell overproduction. Tazi <i>et al</i>., have developed a unified molecular and risk stratification tool for AML, based on the correlation between clinical presentation, cytogenetics and a 32-gene variant signature. This classification proposes an integrated risk score based on 16 molecular classes defined by favourable, intermediate and adverse risks groups. The aim of this retrospective study was to investigate the utility of the AML online calculator to stratify real-world data relating to 159 patients diagnosed with AML in Northern Ireland (NI) between 2017 and 2023 into the appropriate classification and risk group in comparison to their classification under European LeukaemiaNet 2017 guidelines. 15% of patients were reclassified, showing the benefit of incorporating clinical and molecular data into classification and risk stratification models.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Application of the online AML classification and risk stratification calculator in a real-world cohort of AML patients

  • 期刊论文

  • 发表日期：

    2025年12月13日

查看全文
  • Kathryn Clarke,
  • Andrew Hindley,
  • Molly Maguire,
  • Ken Mills,
  • Adam Waterworth,
  • Nicholas Cunningham,
  • Damian Finnegan,
  • Claire Arnold,
  • Mary Frances McMullin,
  • Mark Catherwood

摘要

Acute myeloid leukaemia (AML) is a clonal disorder of the bone marrow, attributable to genetic alterations leading to clonal stem cell overproduction. Tazi et al., have developed a unified molecular and risk stratification tool for AML, based on the correlation between clinical presentation, cytogenetics and a 32-gene variant signature. This classification proposes an integrated risk score based on 16 molecular classes defined by favourable, intermediate and adverse risks groups. The aim of this retrospective study was to investigate the utility of the AML online calculator to stratify real-world data relating to 159 patients diagnosed with AML in Northern Ireland (NI) between 2017 and 2023 into the appropriate classification and risk group in comparison to their classification under European LeukaemiaNet 2017 guidelines. 15% of patients were reclassified, showing the benefit of incorporating clinical and molecular data into classification and risk stratification models.